2024
Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study
Gleason C, Dowling N, Kara F, James T, Salazar H, Simo C, Harman S, Manson J, Hammers D, Naftolin F, Pal L, Miller V, Cedars M, Lobo R, Malek-Ahmadi M, Kantarci K. Long-term cognitive effects of menopausal hormone therapy: Findings from the KEEPS Continuation Study. PLOS Medicine 2024, 21: e1004435. PMID: 39570992, PMCID: PMC11581397, DOI: 10.1371/journal.pmed.1004435.Peer-Reviewed Original ResearchConceptsOral conjugated equine estrogenLatent growth modelingLong-term cognitive effectsCognitive factor scoresCognitive benefitsCognitive performanceFactor scoresBaseline cognitionFollow-upClinical trialsEarly postmenopauseIn-person research visitsYears of follow-upRandomized to placeboMenopausal hormone therapyGlobal cognitive scoreNeuroimaging effectsCognitive measuresCognitive harmLongitudinal cohort studyCognitive changesCognitive slopesCognitive dataTest batteryCognitive functionAging and Adiposity—Focus on Biological Females at Midlife and Beyond
Rehman A, Lathief S, Charoenngam N, Pal L. Aging and Adiposity—Focus on Biological Females at Midlife and Beyond. International Journal Of Molecular Sciences 2024, 25: 2972. PMID: 38474226, PMCID: PMC10931752, DOI: 10.3390/ijms25052972.Peer-Reviewed Original Research
2017
Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel G, Buza N, Pal L. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature. European Journal Of Gynaecological Oncology 2017, 38: 214-220. PMID: 29953783.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansHyperandrogenismHysterectomyMiddle AgedNeoadjuvant TherapyNeoplasm GradingOvarian NeoplasmsOvariectomyPostmenopauseRetrospective StudiesSalpingectomySertoli-Leydig Cell TumorConceptsSertoli-Leydig cell tumorOvarian Sertoli-Leydig cell tumorPresent patient populationDisease-free survivalSingle institution experienceTertiary care institutionTime of diagnosisOnset of menopauseRisk of recurrenceSeries of casesAdjuvant chemotherapyMedian followPostmenopausal bleedingPostmenopausal patientsMedian ageMedian intervalClinical presentationDefinitive managementPathological findingsRetrospective reviewInstitution experiencePatient populationTreatment modalitiesCell tumorsTumor grade